Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2026 grant income of CHF 0.310 million, up from CHF 0.261 million a year earlier, while basic and diluted loss per share narrowed to CHF 0.16 from CHF 0.49. Net loss fell sharply despite a wider operating loss because warrant remeasurement and foreign-exchange gains produced a positive finance result. Meanwhile, the company advanced its two registrational programs and ended June with CHF 228.3 million in cash and short-term investments.

Core Financial Results

Oculis reported no product revenue for the quarter, with grant income representing its operating income. Operating expenses increased by approximately 13.5% to CHF 23.878 million, primarily because of headcount-related costs, including share-based compensation, needed to support the company’s development programs.

The operating loss widened by approximately 13.5%, but the net loss narrowed by about 60.7%. This divergence resulted from a CHF 12.100 million fair-value gain on warrant liabilities and a CHF 1.221 million foreign-exchange gain, compared with losses from both items in the prior-year quarter.

The lower quarterly net loss therefore did not reflect improved operating profitability. The underlying cost base increased, with G&A accounting for most of the year-over-year rise in operating expenses.

Pipeline Progress and Strategic Pivot

Privosegtor becomes the lead late-stage program

Oculis continued its pivot toward neuro-ophthalmology, positioning Privosegtor as its lead late-stage asset. Site activation for the registrational PIONEER-1 optic neuritis trial is progressing across the U.S., Europe, Australia, and Canada.

Under the Special Protocol Assessment agreed with the FDA, PIONEER-1’s primary endpoint is the proportion of patients achieving at least a 15-letter improvement in low-contrast visual acuity at Month 3. Patients will continue to be followed through Month 12 for long-term safety and tolerability.

Privosegtor may also expand into acute multiple sclerosis relapses. The FDA’s Division of Neurology indicated that Oculis will not need additional preclinical studies before submitting an investigational new drug application that cross-references the existing optic neuritis filing. Oculis expects to submit that IND in Q4 2026 and plans an R&D Day during the quarter to provide further development updates.

Licaminlimab enrollment passes 45%

All planned sites are active in the PREDICT-1 registrational trial of Licaminlimab for dry eye disease, and more than 45% of patients have been randomized. The study plans to enroll approximately 160 patients, around two-thirds of whom are expected to carry the specified TNFR1 genotype.

The primary endpoint measures the change in global ocular discomfort severity through Day 29 among patients with the specified genotype. Oculis expects topline results around the end of 2026. The genotype-based design is intended to identify patients more likely to respond, although the company acknowledged that measurements of dry-eye symptoms are inherently subjective.

OCS-01 development narrows

Following the DIAMOND topline results announced in May, Oculis said it does not currently plan to pursue an FDA filing for OCS-01 in diabetic macular edema. This decision further concentrates the late-stage pipeline on Privosegtor and Licaminlimab.

Liquidity and Balance Sheet

Cash, cash equivalents, and short-term investments totaled CHF 228.3 million, or $282.3 million, at June 30, 2026. That compares with CHF 213.0 million, or $268.7 million, at December 31, 2025, representing an increase of approximately 7.2% in Swiss-franc terms.

The increase came from year-to-date sales of ordinary shares through Oculis’ existing at-the-market offering program, partially offset by operating expenses. Management expects the available liquidity to fund operations into the second half of 2029, covering the company’s currently identified clinical and regulatory milestones.

Warrant liabilities declined to CHF 7.819 million from CHF 14.478 million at year-end. The lower market value of those liabilities contributed to the fair-value gain that reduced the reported net loss, but it did not reverse the increase in clinical-stage operating costs.

Risks Investors Should Monitor

• Privosegtor execution risk: PIONEER-1 remains dependent on global site activation and coordination among emergency physicians, ophthalmologists, and neurologists. Oculis is also seeking to capture peak enrollment periods tied to the seasonality of optic neuritis.
• Clinical and regulatory uncertainty: Positive FDA feedback supports Privosegtor’s proposed development pathway in acute MS relapses, but it does not establish clinical efficacy or guarantee regulatory approval.
• PREDICT-1 endpoint risk: Licaminlimab’s primary analysis focuses on a genotype-defined subgroup and uses a subjective symptom measure, making the year-end topline result an important test of the precision-medicine strategy.
• Greater pipeline concentration: The decision not to pursue an OCS-01 DME filing leaves Oculis more dependent on successful development of Privosegtor and Licaminlimab.
• Rising operating costs and financing dependence: The operating loss widened and G&A expenses increased by approximately 40.4%. Liquidity improved primarily because of ordinary-share sales rather than operating income.

Summary

Oculis’ Q2 2026 results showed higher development-stage operating costs but a substantially narrower net loss because of favorable warrant and currency movements. The investment case now centers more heavily on execution of the Privosegtor and Licaminlimab registrational programs, including the planned acute MS relapse IND and PREDICT-1 topline results, while the CHF 228.3 million liquidity position provides management-estimated runway into the second half of 2029.